These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25435339)

  • 1. Synergism between asymmetric dimethylarginine (ADMA) and a genetic marker of uric acid in CKD progression.
    Testa A; Mallamaci F; Leonardis D; Spoto B; Pisano A; Sanguedolce MC; Tripepi G; Zoccali C;
    Nutr Metab Cardiovasc Dis; 2015 Feb; 25(2):167-72. PubMed ID: 25435339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of a polymorphism in a gene encoding a urate transporter with CKD progression.
    Testa A; Mallamaci F; Spoto B; Pisano A; Sanguedolce MC; Tripepi G; Leonardis D; Zoccali C
    Clin J Am Soc Nephrol; 2014 Jun; 9(6):1059-65. PubMed ID: 24742479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A genetic marker of hyperuricemia predicts cardiovascular events in a meta-analysis of three cohort studies in high risk patients.
    Testa A; Prudente S; Leonardis D; Spoto B; Sanguedolce MC; Parlongo RM; Tripepi G; Rizza S; Mallamaci F; Federici M; Trischitta V; Zoccali C
    Nutr Metab Cardiovasc Dis; 2015 Dec; 25(12):1087-94. PubMed ID: 26607700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A genetic marker of uric acid level, carotid atherosclerosis, and arterial stiffness: a family-based study.
    Mallamaci F; Testa A; Leonardis D; Tripepi R; Pisano A; Spoto B; Sanguedolce MC; Parlongo RM; Tripepi G; Zoccali C
    Am J Kidney Dis; 2015 Feb; 65(2):294-302. PubMed ID: 25301104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of uric acid and asymmetric dimethylarginine for modeling cardiovascular risk prediction in chronic kidney disease patients.
    Kanbay M; Afsar B; Siriopol D; Unal HU; Karaman M; Saglam M; Eyileten T; Gezer M; Verim S; Oguz Y; Vural A; Ortiz A; Johnson RJ; Covic A; Yilmaz MI
    Int Urol Nephrol; 2016 Jul; 48(7):1129-36. PubMed ID: 27007614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic renal impairment and DDAH2-1151 A/C polymorphism determine ADMA levels in type 2 diabetic subjects.
    Marra M; Marchegiani F; Ceriello A; Sirolla C; Boemi M; Franceschi C; Spazzafumo L; Testa I; Bonfigli AR; Cucchi M; Testa R
    Nephrol Dial Transplant; 2013 Apr; 28(4):964-71. PubMed ID: 23129820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease.
    Emrich IE; Zawada AM; Martens-Lobenhoffer J; Fliser D; Wagenpfeil S; Heine GH; Bode-Böger SM
    Clin Res Cardiol; 2018 Mar; 107(3):201-213. PubMed ID: 29101459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study.
    Fliser D; Kronenberg F; Kielstein JT; Morath C; Bode-Böger SM; Haller H; Ritz E
    J Am Soc Nephrol; 2005 Aug; 16(8):2456-61. PubMed ID: 15930091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Competitive interaction between fibroblast growth factor 23 and asymmetric dimethylarginine in patients with CKD.
    Tripepi G; Kollerits B; Leonardis D; Yilmaz MI; Postorino M; Fliser D; Mallamaci F; Kronenberg F; Zoccali C
    J Am Soc Nephrol; 2015 Apr; 26(4):935-44. PubMed ID: 25150156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Significance of the factors of hypoxia and endothelial dysfunction in kidney injury in the presence of obesity].
    Galiamov MG; Saginova EA; Severova MM; Samokhodskaia LM; Krasnova TN; Sholomova VI; Sorokin IuD; Mukhin NA
    Ter Arkh; 2013; 85(6):31-7. PubMed ID: 23866596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperuricemia and Progression of CKD in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort Study.
    Rodenbach KE; Schneider MF; Furth SL; Moxey-Mims MM; Mitsnefes MM; Weaver DJ; Warady BA; Schwartz GJ
    Am J Kidney Dis; 2015 Dec; 66(6):984-92. PubMed ID: 26209544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asymmetric dimethylarginine and progression of chronic kidney disease: a one-year follow-up study.
    Eiselt J; Rajdl D; Racek J; Vostrý M; Rulcová K; Wirth J
    Kidney Blood Press Res; 2014; 39(1):50-7. PubMed ID: 24923294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arginine, dimethylated arginine and homoarginine in relation to cardiovascular risk in patients with moderate chronic kidney disease.
    Hov GG; Aasarød KI; Sagen E; Åsberg A
    Clin Biochem; 2015 Jul; 48(10-11):646-51. PubMed ID: 25828044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. J-shaped mortality relationship for uric acid in CKD.
    Suliman ME; Johnson RJ; García-López E; Qureshi AR; Molinaei H; Carrero JJ; Heimbürger O; Bárány P; Axelsson J; Lindholm B; Stenvinkel P
    Am J Kidney Dis; 2006 Nov; 48(5):761-71. PubMed ID: 17059995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperuricemia contributes to the faster progression of diabetic kidney disease in type 2 diabetes mellitus.
    Bartáková V; Kuricová K; Pácal L; Nová Z; Dvořáková V; Švrčková M; Malúšková D; Svobodová I; Řehořová J; Svojanovský J; Olšovský J; Bělobrádková J; Kaňková K
    J Diabetes Complications; 2016; 30(7):1300-7. PubMed ID: 27324705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Uric Acid Levels on Kidney Disease Progression.
    Rincon-Choles H; Jolly SE; Arrigain S; Konig V; Schold JD; Nakhoul G; Navaneethan SD; Nally JV; Rothberg MB
    Am J Nephrol; 2017; 46(4):315-322. PubMed ID: 29032376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uric acid and incident chronic kidney disease in a large health check-up population in Taiwan.
    Wang S; Shu Z; Tao Q; Yu C; Zhan S; Li L
    Nephrology (Carlton); 2011 Nov; 16(8):767-76. PubMed ID: 21854506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A polymorphism in the major gene regulating serum uric acid associates with clinic SBP and the white-coat effect in a family-based study.
    Mallamaci F; Testa A; Leonardis D; Tripepi R; Pisano A; Spoto B; Sanguedolce MC; Parlongo RM; Tripepi G; Zoccali C
    J Hypertens; 2014 Aug; 32(8):1621-8; discussion 1628. PubMed ID: 24805955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of uric acid and left ventricular mass index with renal outcomes in chronic kidney disease.
    Chen SC; Chang JM; Yeh SM; Su HM; Chen HC
    Am J Hypertens; 2013 Feb; 26(2):243-9. PubMed ID: 23382409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - possible candidates for paradoxical epidemiology?
    Busch M; Fleck C; Wolf G; Stein G
    Amino Acids; 2006 May; 30(3):225-32. PubMed ID: 16680555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.